Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Helicobacter Pylori Infections - Pipeline Review, Q3 2011

VIEWS: 8 PAGES: 69

Helicobacter Pylori Infections - Pipeline Review, Q3 2011 Summary Global Markets Direct’s, 'Helicobacter Pylori Infections - Pipeline Review, Q3 2011', provides an overview of the Helicobacter Pylori Infections therapeutic pipeline. This report provides information on the therapeutic development for Helicobacter Pylori Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Helicobacter Pylori Infections. 'Helicobacter Pylori Infections - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Helicobacter Pylori Infections. - A review of the Helicobacter Pylori Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Helicobacter Pylori Infections pipeline on the basis of therapeutic class, route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeu

More Info
  • pg 1
									Helicobacter Pylori Infections – Pipeline Review, Q3 2011




     Helicobacter Pylori Infections - Pipeline Review, Q3
                             2011
                                                                                          Reference Code: GMDHC1155IDB

                                                                                          Publication Date: July 2011




Helicobacter Pylori Infections – Pipeline Review, Q3 2011                                                               GMDHC1155IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
                                                                                                                                             Page(1)
Helicobacter Pylori Infections – Pipeline Review, Q3 2011



Ta b le o f Co n te n ts
Table of Contents                                                                                                              2
List of Tables                                                                                                                 5
List of Figures                                                                                                                6
Introduction                                                                                                                   7
     Global Markets Direct Report Coverage                                                                                     7
Helicobacter Pylori Infections Overview                                                                                        8
Therapeutics Development                                                                                                       9
     An Overview of Pipeline Products for Helicobacter Pylori Infections                                                       9
Helicobacter Pylori Infections Therapeutics under Development by Companies                                                    11
Helicobacter Pylori Infections Therapeutics under Investigation by Universities/Institutes                                    13
Late Stage Products                                                                                                           15
     Comparative Analysis                                                                                                     15
Mid Clinical Stage Products                                                                                                   16
     Comparative Analysis                                                                                                     16
Early Clinical Stage Products                                                                                                 17
     Comparative Analysis                                                                                                     17
Pre-Clinical Stage Products                                                                                                   18
     Comparative Analysis                                                                                                     18
Helicobacter Pylori Infections Therapeutics - Products under Development by Companies                                         19
Helicobacter Pylori Infections Therapeutics - Products under Investigation by Universities/Institutes                         20
Companies Involved in Helicobacter Pylori Infections Therapeutics Development                                                 21
     Sequella, Inc.                                                                                                           21
     Novartis AG                                                                                                              21
     Callisto Pharmaceuticals, Inc.                                                                                           22
     Deva Holding A.S.                                                                                                        22
     EastPharma Ltd.                                                                                                          23
     MerLion Pharmaceuticals Pte Ltd                                                                                          23
     Vecta Ltd.                                                                                                               24
Helicobacter Pylori Infections - Therapeutics Assessment                                                                      25
     Assessment by Monotherapy Products                                                                                       25
     Assessment by Combination Products                                                                                       26
     Assessment by Route of Administration                                                                                    27
     Assessment by Molecule Type                                                                                              29
Drug Profiles                                                                                                                 31
     SQ 109 - Drug Profile                                                                                                    31
          Product Description                                                                                                 31
          Mechanism of Action                                                                                                 31
          R&D Progress                                                                                                        31
     AVEC - Drug Profile                                                                                                      33
          Product Description                                                                                                 33
          Mechanism of Action                                                                                                 33
          R&D Progress                                                                                                        33
     Rifalazil - Drug Profile                                                                                                 34
          Product Description                                                                                                 34
          Mechanism of Action                                                                                                 34
          R&D Progress                                                                                                        34
     Helicobacter Pylori Vaccine - Drug Profile                                                                               36


Helicobacter Pylori Infections – Pipeline Review, Q3 2011                                               GMDHC1155IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                      Page(2)
Helicobacter Pylori Infections – Pipeline Review, Q3 2011


          Product Description                                                                                     36
          Mechanism of Action                                                                                     36
          R&D Progress                                                                                            36
     Lansoprazole + Amoxicillin + Clarithromycin + Metronidazole - Drug Profile                                   37
          Product Description                                                                                     37
          Mechanism of Action                                                                                     37
          R&D Progress                                                                                            37
     GT08 - Drug Profile                                                                                          38
          Product Description                                                                                     38
          Mechanism of Action                                                                                     38
          R&D Progress                                                                                            38
     Levofloxacin + Amoxicillin + Lansoprazole - Drug Profile                                                     39
          Product Description                                                                                     39
          Mechanism of Action                                                                                     39
          R&D Progress                                                                                            39
     Finafloxacin - Drug Profile                                                                                  40
          Product Description                                                                                     40
          Mechanism of Action                                                                                     40
          R&D Progress                                                                                            40
     NCA 600 mg - Drug Profile                                                                                    41
          Product Description                                                                                     41
          Mechanism of Action                                                                                     41
          R&D Progress                                                                                            41
     Ferric Pyrophosphate - Drug Profile                                                                          42
          Product Description                                                                                     42
          Mechanism of Action                                                                                     42
          R&D Progress                                                                                            42
     Ferrous Fumarate - Drug Profile                                                                              43
          Product Description                                                                                     43
          Mechanism of Action                                                                                     43
          R&D Progress                                                                                            43
     Finafloxacin + Amoxicillin - Drug Profile                                                                    44
          Product Description                                                                                     44
          Mechanism of Action                                                                                     44
          R&D Progress                                                                                            44
     Finafloxacin + Esomeprazole - Drug Profile                                                                   45
          Product Description                                                                                     45
          Mechanism of Action                                                                                     45
          R&D Progress                                                                                            45
     Amoxicillin + Metronidazole + Omeprazole + Bismuth + Protexin Protect - Drug Profile                         46
          Product Description                                                                                     46
          Mechanism of Action                                                                                     46
          R&D Progress                                                                                            46
     Nigella Sativa Seeds + Omeprazole - Drug Profile                                                             48
          Product Description                                                                                     48
          Mechanism of Action                                                                                     48
          R&D Progress                                                                                            48
     Clarithromycin + Amoxicillin + Omeprazole - Drug Profile                                                     49




Helicobacter Pylori Infections – Pipeline Review, Q3 2011                                   GMDHC1155IDB / Pub July 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                          Page(3)
Helicobacter Pylori Infections – Pipeline Review, Q3 2011


          Product Description                                                                                                             49
          Mechanism of Action                                                                                                             49
          R&D Progress                                                                                                                    49
     Omeprazole + Amoxicillin + Clarithromycin - Drug Profile                                                                             51
          Product Description                                                                                                             51
          Mechanism of Action                                                                                                             51
          R&D Progress                                                                                                                    51
     Omeprazole + Amoxicillin + Azithromycin - Drug Profile                                                                               52
          Product Description                                                                                                             52
          Mechanism of Action                                                                                                             52
          R&D Progress                                                                                                                    52
     Omeprazol + Amoxycilin + Clarithromycin - Drug Profile                                                                               54
          Product Description                                                                                                             54
          Mechanism of Action                                                                                                             54
          R&D Progress                                                                                                                    54
     Metronidazole + Amoxicillin + Bismuth + Omeprazole - Drug Profile                                                                    55
          Product Description                                                                                                             55
          Mechanism of Action                                                                                                             55
          R&D Progress                                                                                                                    55
     RHB 105 - Drug Profile                                                                                                               57
          Product Description                                                                                                             57
          Mechanism of Action                                                                                                             57
          R&D Progress                                                                                                                    57
     Levofloxacin + Amoxicillin + Lansoprazole - Drug Profile                                                                             59
          Product Description                                                                                                             59
          Mechanism of Action                                                                                                             59
          R&D Progress                                                                                                                    59
Helicobacter Pylori Infections Therapeutics – Drug Profile Updates                                                                        60
     Helicobacter Pylori Infections - Featured News                                                                                       62
          Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers     62
          Oct 29, 2010: AstraZeneca announces co-promotion agreement with Daiichi Sankyo for NEXIUM in Japan                              62
          Sep 27, 2010: TrioBiotics Pharma AG Announces Receipt Of Notice Of Allowance Of Patent For Rifalazil For Method Of Treatment And
          Prophylactic Use                                                                                                                 63
          Aug 09, 2010: TrioBiotics Pharma AG Announces New Strate
								
To top